Addex Therapeutics Ltd (NASDAQ:ADXN) Short Interest Up 425.7% in November

Addex Therapeutics Ltd (NASDAQ:ADXN) was the recipient of a large increase in short interest in November. As of November 15th, there was short interest totalling 18,400 shares, an increase of 425.7% from the October 31st total of 3,500 shares. Currently, 2.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 305,400 shares, the days-to-cover ratio is currently 0.1 days.

Addex Therapeutics Trading Down 1.8 %

Shares of Addex Therapeutics stock opened at $8.62 on Thursday. The firm has a market capitalization of $9.14 million, a PE ratio of -5.26 and a beta of 1.78. Addex Therapeutics has a 12 month low of $5.00 and a 12 month high of $27.90. The business’s 50-day moving average price is $9.81 and its 200-day moving average price is $9.07.

Addex Therapeutics (NASDAQ:ADXN) last issued its earnings results on Monday, September 30th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($1.70). The firm had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $0.26 million. Addex Therapeutics had a negative return on equity of 112.43% and a net margin of 850.30%. As a group, analysts predict that Addex Therapeutics will post 9.8 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Addex Therapeutics in a research report on Wednesday, October 2nd.

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.